SAN DIEGO–(BUSINESS WIRE)–KFx Medical Corporation
today announced that it was granted a new patent from the United States Patent
and Trademark Office: U.S. Patent No. 8,100,942 broadly covering knotless
double row rotator cuff repair. The new patent bolsters KFx Medicals patent
portfolio and highlights KFx Medicals innovation in the orthopaedic and medical
In 2011, an anonymous party filed a request that the
Patent Office re-examine KFxs first and seminal patent (U.S. Pat. No.
7,585,311) which also broadly covers knotless double row rotator cuff repair.
The Patent Office rejected all arguments made by the anonymous party and
completely upheld the KFx patent.
“This new patent further increases the value and importance
of KFx Medicals patent portfolio for the clinically important area of knotless
double row rotator cuff repair,” indicated Tate Scott, KFx Medical president
and CEO. “Our patent counsel, Knobbe Martens, has done an excellent job in
executing our strategy to protect the inventions as described in our patent estate.
With each patent, we demonstrate our ongoing commitment to innovation in
orthopaedic surgery so that our investors and employees may be rewarded for
The new AppianFx line of implants from KFx are used to
reattach tissue to and in bone during shoulder, knee, foot and ankle procedures
which combined exceed well over 1 million annual surgical procedures in the
United States. Product offerings include those that directly place and secure
tissue into bone both with and without the use of sutures.
For additional information about KFx Medical Corporation,
About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded
in 2003 to develop tissue fixation and bone implant products used in a variety
of orthopedic surgical procedures performed on the shoulder, knee, foot, and
ankle. KFx provides simple solutions for orthopedic surgeons specializing in
sports medicine. The company is privately held – investors include Alloy
Ventures , Charter Life Sciences , Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.
Posted by Sean Fenske, Editor-in-Chief, MDT